Pharmacologic levels of nitrendipine do not affect actin-myosin interaction in the human uterus and placenta.
Because of the potential of dihydropyridine calcium channel blockers in the management of premature labor, we have studied the direct effects of nitrendipine on actomyosin in the pregnant and nonpregnant uterus and in the term human placenta. Actomyosin adenosinetriphosphatase in the three tissues and another model of actin-myosin interaction, superprecipitation of placental actomyosin, were inhibited by nitrendipine. The inhibition was not diminished by high concentrations of calcium. To identify the mechanism, placental myosin was phosphorylated in the absence and presence of 0.8 X 10(-4) mol/L of nitrendipine. The myosin phosphorylated in the presence of nitrendipine had lower actin-activated adenosinetriphosphatase, which is consistent with the inhibition of myosin light chain phosphorylation. However, nitrendipine did not affect the adenosinetriphosphatase activity of myosin nor did further reduce the adenosinetriphosphatase of the already phosphorylated placental actomyosin. Thus nitrendipine inhibition is directed to the phosphorylation reaction but not to the adenosinetriphosphatase site of myosin. Myometrial relaxation in vivo or in vitro occurs at the pharmacologic nitrendipine levels of 10(-9) to 10(-8) mol/L, which is at least 10,000 times lower than that of the concentration of 50% inhibition of myosin light chain phosphorylation (0.0026 +/- 0.00015 mol/L of nitrendipine, mean +/- SEM) demonstrated in the present work. Because of this difference, the direct intracellular actions of dihydropyridine calcium channel blockers are not expected to cause adverse effects in the uteroplacental system when these drugs are used in the prevention or treatment of premature labor.